Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Biohaven Ltd. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
BHVN
New York
2830
www.biohaven.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Biohaven Ltd.
Roche’s AI lab; Biohaven’s pivotal pause
- Oct 2nd, 2026 7:54 am
Why Did Regeneron Pharmaceuticals (REGN) Stock Drop Today?
- Sep 29th, 2026 3:07 am
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
- Sep 28th, 2026 5:30 am
Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?
- Sep 25th, 2026 3:08 pm
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain.
- Sep 18th, 2026 12:34 pm
Warby Parker’s Unusual Options Activity Points to a Covered Call Bet: Bullish on Growth, Cautious on Valuation
- Sep 18th, 2026 11:30 am
Biohaven’s epilepsy drug hit with FDA clinical hold
- Sep 11th, 2026 5:17 am
Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback
- Sep 10th, 2026 2:17 pm
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
- Sep 10th, 2026 12:14 pm
FDA places partial hold on Biohaven’s epilepsy drug
- Sep 10th, 2026 10:13 am
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials
- Sep 10th, 2026 8:10 am
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?
- Sep 10th, 2026 7:45 am
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says
- Sep 8th, 2026 10:29 am
Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target
- Sep 8th, 2026 4:53 am
Biohaven (BHVN) Cashes In On Its Biggest Epilepsy Bet
- Sep 3rd, 2026 5:59 am
Why Biohaven Stock Was Rocking the Market This Week
- Aug 28th, 2026 1:32 am
Slate Medicines Starts Migraine Treatment Study
- Aug 27th, 2026 3:49 pm
SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race
- Aug 27th, 2026 8:40 am
BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program
- Aug 27th, 2026 7:42 am
Scroll